LeMaitre Vascular, Inc. (LMAT) Plans Quarterly Dividend of $0.06
LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend on Monday, October 30th, Wall Street Journal reports. Investors of record on Wednesday, November 22nd will be given a dividend of 0.055 per share by the medical instruments supplier on Thursday, December 7th. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date is Tuesday, November 21st.
LeMaitre Vascular (NASDAQ:LMAT) traded down 1.15% during trading on Monday, hitting $30.90. The company had a trading volume of 401,152 shares. The company has a market capitalization of $587.78 million, a price-to-earnings ratio of 44.14 and a beta of 0.67. LeMaitre Vascular has a 12-month low of $19.82 and a 12-month high of $39.88. The firm has a 50-day moving average of $37.64 and a 200 day moving average of $32.61.
LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.05. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The firm had revenue of $24.80 million during the quarter, compared to analysts’ expectations of $25.49 million. During the same period in the previous year, the firm earned $0.17 earnings per share. The company’s revenue was up 6.9% on a year-over-year basis. On average, equities research analysts forecast that LeMaitre Vascular will post $0.82 earnings per share for the current year.
In other news, Director Lawrence J. Jasinski sold 2,030 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $34.23, for a total transaction of $69,486.90. Following the completion of the transaction, the director now directly owns 8,333 shares of the company’s stock, valued at $285,238.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Peter R. Gebauer sold 22,067 shares of the company’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $34.28, for a total value of $756,456.76. Following the transaction, the insider now directly owns 4,486 shares of the company’s stock, valued at $153,780.08. The disclosure for this sale can be found here. Insiders have sold 373,121 shares of company stock valued at $12,825,992 over the last ninety days. 23.70% of the stock is owned by insiders.
LeMaitre Vascular declared that its board has initiated a share repurchase plan on Thursday, July 27th that allows the company to repurchase $7.50 million in shares. This repurchase authorization allows the medical instruments supplier to purchase up to 1.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.
A number of research analysts have issued reports on the company. Canaccord Genuity decreased their target price on LeMaitre Vascular from $30.00 to $29.00 and set a “hold” rating for the company in a research note on Friday. First Analysis cut LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 target price for the company. in a research note on Friday. Stifel Nicolaus reissued a “buy” rating on shares of LeMaitre Vascular in a research note on Sunday. Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, September 28th. Finally, BidaskClub cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Seven analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $32.80.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.